Amylin Pharmaceuticals Financial Statements
Amylin Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Amylin Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 840.1 | 781.0 | 510.9 |
| Gross Profit ($ mil.) | 748.5 | 715.5 | 460.8 |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | (315.4) | (211.1) | (218.9) |
| Diluted EPS (Net Income) | (2.30) | (1.59) | (1.78) |
Amylin Pharmaceuticals Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 211.2 | 209.4 | 193.7 |
| Gross Profit ($ mil.) | 188.6 | 185.1 | 175.0 |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | (26.7) | (62.4) | (47.0) |
| Diluted EPS (Net Income) | (0.19) | (0.44) | (0.34) |
Amylin Pharmaceuticals Stock Quote & Chart
11/06/09 16:00:00 EST •
NASDAQ •
12.07
•
 +0.0400
•
+0.3325 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Amylin Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 2.03 | 7.49 | 7.00 |
| Price/Earnings Ratio | (5.81) | 92.59 | 25.45 |
| Price/Book Ratio | 3.67 | 3.46 | 6.74 |
| Price/Cash Flow Ratio | (39.68) | 41.15 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Amylin Pharmaceuticals Financial Ratios
Amylin Pharmaceuticals Competitive Intelligence
| GlaxoSmithKline | Merck | Novo Nordisk | |
|---|---|---|---|
| Annual Sales ($ mil.) | 35,244.6 | 18,502.0 | 8,627.7 |
| Employees | 99,003 | 51,000 | 26,600 |
| Market Cap ($ mil.) | 114,528.4 | 46,142.1 | 40,937.4 |
Competitive Landscape
